|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvalYear
|
2013
|
|
gptkbp:ATCCode
|
gptkb:J05AP08
|
|
gptkbp:availableOn
|
gptkb:Canada
gptkb:European_Union
gptkb:Japan
gptkb:United_States
|
|
gptkbp:brand
|
gptkb:Sovaldi
|
|
gptkbp:CASNumber
|
1190307-88-0
|
|
gptkbp:contraindication
|
gptkb:phenytoin
gptkb:rifampin
gptkb:carbamazepine
gptkb:St._John's_Wort
gptkb:oxcarbazepine
phenobarbital
|
|
gptkbp:developedBy
|
gptkb:Gilead_Sciences
|
|
gptkbp:eliminationHalfLife
|
0.4 hours (sofosbuvir), 27 hours (GS-331007)
|
|
gptkbp:hasInChIKey
|
YYOQXSRSLFDJOM-QZIXMDIESA-N
|
|
gptkbp:hasMolecularFormula
|
C22H29FN3O9P
|
|
gptkbp:hasPatentExpiry
|
2029 (US)
|
|
gptkbp:hasSMILES
|
CC(C)COC(=O)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](NC(=O)COC1=CN(C2C1C(C(O2)COP(=O)(O)O)O)C)C)C
|
|
gptkbp:hasUNII
|
Q1Q1XK97B3
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
DB09314
|
|
gptkbp:indication
|
treatment of chronic hepatitis C infection
|
|
gptkbp:isPregnancyCategory
|
Not assigned (US)
B1 (Australia)
|
|
gptkbp:isUsedInCombinationWith
|
gptkb:daclatasvir
ribavirin
ledipasvir
velpatasvir
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
NS5B RNA-dependent RNA polymerase inhibitor
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
529.45
|
|
gptkbp:name
|
gptkb:Sofosbuvir
|
|
gptkbp:proteinBinding
|
61-65%
|
|
gptkbp:PubChem_CID
|
gptkb:DB09314
gptkb:D10366
45375808
29342046
CHEMBL1257078
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:anemia
nausea
fatigue
headache
insomnia
|
|
gptkbp:status
|
true
|
|
gptkbp:synonym
|
gptkb:GS-7977
gptkb:PSI-7977
|
|
gptkbp:target
|
gptkb:HCV_NS5B_polymerase
|
|
gptkbp:bfsParent
|
gptkb:Protamine_sulfate
|
|
gptkbp:bfsLayer
|
6
|